Combi-molecules: A global approach towards better chemoselectivity and chemosensitivity;Le concept de « combi-ciblage »: Une approche globale pour l'amélioration de la chimiosélectivité des agents cytotoxiques et pour renverser la chimiorésistance des tumeurs réfractaires

Bulletin du Cancer

Volumn 91, Issue 12, 2004, Pages 911-915

  Matheson, Stéphanie ^a   Qiu, Qiyu ^a   Brahimi, Fouad ^a   Dudouit, Fabienne ^a   Banerjee, Ranjita ^a   Rachid, Zakaria ^a   Jean Claude, Bertrand J ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Chemoselectivity; Combi targeted; Epidermal growth factor; Temozolide

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANTINEOPLASTIC AGENT; BJ 2000; CARMUSTINE; CELL DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FD 110; FD 137; QUINAZOLINE DERIVATIVE; RB 24; SMA 41; SMA 52; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ZR 01; ZR 08; ALKYLATING AGENT; DNA; FD137 CPD; NITROSOUREA DERIVATIVE; SMA-41;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CELL PROLIFERATION; DNA DAMAGE; DRUG RESEARCH; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; IC 50; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; REVIEW; STRUCTURE ACTIVITY RELATION; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; SYNTHESIS;

ANTINEOPLASTIC AGENTS, ALKYLATING; DNA DAMAGE; DNA, NEOPLASM; NITROSOUREA COMPOUNDS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 12844259426     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Eisenbrand G, Berger MR, Fisher J, Schneider MR, Tang W, Aller WJ. Development of more selective anti-cancer nitrosoureas. Anticancer Drug Des 1988; 2: 351-9.
2. Monneret C, Florent JC. Targeting of antitumor drugs with monoclonal antibodies. Bull Cancer 2000; 87: 829-38.
3. Bagshawe KD. Antibody-directed enzyme prodrug therapy (ADEPT). Adv Pharmacol 1993; 24: 99-118.
4. Blakey DC, Burke PJ, Davies DH, Dowell RI, Melton RG, Springer CJ, et al. Antibody-directed enzyme prodrug therapy (ADEPT) for treatment of major solid tumor disease. Biochem Soc Trans 1995; 23: 1047-50.
5. Van de Loosdrecht AA, Huijgens PC, Ossenkippele GJ. Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implications. Anti-Cancer Drugs 2004; 15: 189-201.
6. Matheson S, McNamee J, Jean-Claude BJ. Design of achimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumour targeting strategy. J Pharm Exp Ther 2001; 296: 832-40.
7. Brahimi F, Matheson S, McNamee J, Tari A, Jean-Claude BJ. Inhibition of epidermal growth factor receptor-mediated signaling by "combi- triazene" BJ2000, a new probe for the Combi-Targeting postulates. J Pharm Exp Ther 2002; 303: 238-46.
8. Rachid Z, Brahimi F, Teoh N, Jean-Claude BJ. The Combi-Targeting concept: chemical dissection of the dual targeting properties of a series of "combi-triazenes". J Med Chem 2003; 46: 4313-21.
9. Penault-Llorca F. REGF/Méthodes d'évaluation du statut et expression tumorale. Bull Cancer 2003; 90: S186-S191.
10. Penault-Llorca F, Durando X, Bay JO. Valeut pronostique du REGF. Bull Cancer 2003; 90: S192-S196.
11. Diéras V, Pierga JY, Vincent-Salomon A, Beuzeboc P, Pouillart P, de Cremoux P. Ciblage du REGF dans les cancers du Sein. Bull Cancer 2003; 90: S257-S262.
12. 14C]-methyl triazene: a tadiolabeled probe for the combi-targeting concept. J Label Comp Radiopharm 2003; 46: 729-35.
13. Qiu Q, Dudouit F, Matheson SL, Brahimi F, Banerjee R, McNamee JP, et al. The Combi-Targeting Concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitoty properties. Cancer Chemother Pharmacol 2003; 51: 1-10.
14. Matheson SL, Brahimi F, Jean-Claude BJ. The combi-targeting concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting "combi-triazene" SMA41. Biochem Pharm 2004; 67: 1131-8.
15. Fornace AJ, Papathanasiou MA, Hollander MC, Yarosh DB. Expression of rhe O6-methylguanine-DNA-methyltransferase gene MGMT in Mer+ and Mer- human rumor cells. Cancer Res 1990; 50: 7908-11.
16. Bishop PC, Myers TG, Fry DW, Liu ETL, Bagosconny M, Bates SE. Differential sensitivity of cancer cells to inhibitors of epidermal growth factor family. Oncogene 2002; 21: 119-25.
17. Matheson SL, McNamee J, Jean-Claude BJ. Differential responses of EGFR-/-AGT-expressing cells to the "combi-triazene" SMA41. Cancer Chemother Pharmacol 2003; 51: 11-20.
18. Banerjee R, Rachid Z, McNamee J, Jean-Claude BJ. Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting concept. J Med Chem 2003; 46: 5546-51.